Squadron Capital Management
Latest statistics and disclosures from Squadron Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RLMD, CCCC, COGT, ZNTL, KOD, and represent 49.44% of Squadron Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CCCC (+$25M), BIOA (+$9.9M), CMPS (+$8.6M), ELVN (+$8.1M), IVA (+$7.2M), RZLT (+$6.8M), ADAG (+$5.3M), FBRX, KOD, IFRX.
- Started 20 new stock positions in Scynexis, IRON, NMRA, NVCT, ADAG, PRQR, Quince Therapeutics, ELVN, CMPS, CTNM. RZLT, INM, CUE, FBRX, IFRX, BIOA, CALC, DFTX, RARE, ASMB.
- Reduced shares in these 10 stocks: Kalvista Pharmaceuticals (-$26M), ABVX (-$15M), NKTR (-$9.0M), RLMD (-$7.8M), IDYA (-$7.5M), SCYX (-$7.0M), ANL (-$5.8M), EPRX, GHRS, KPTI.
- Sold out of its positions in ALXO, ABVX, CNTX, EPRX, IDYA, Kalvista Pharmaceuticals, KPTI, NKTR, NEUP, TRAW. SCYX, SPRB, TXMD, HOWL, GHRS.
- Squadron Capital Management was a net buyer of stock by $21M.
- Squadron Capital Management has $322M in assets under management (AUM), dropping by 18.07%.
- Central Index Key (CIK): 0002050709
Tip: Access up to 7 years of quarterly data
Positions held by Squadron Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Squadron Capital Management
Squadron Capital Management holds 38 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relmada Therapeutics (RLMD) | 15.8 | $51M | -13% | 7.4M | 6.92 |
|
| C4 Therapeutics Com Stk (CCCC) | 11.0 | $36M | +237% | 7.6M | 4.67 |
|
| Cogent Biosciences (COGT) | 10.4 | $34M | +9% | 865k | 38.70 |
|
| Zentalis Pharmaceuticals Call Option (ZNTL) | 6.2 | $20M | +2% | 4.1M | 4.85 |
|
| Kodiak Sciences (KOD) | 6.0 | $20M | +31% | 500k | 38.96 |
|
| Relay Therapeutics (RLAY) | 5.6 | $18M | +17% | 970k | 18.71 |
|
| Edgewise Therapeutics (EWTX) | 3.7 | $12M | -17% | 290k | 40.63 |
|
| Maze Therapeatics (MAZE) | 3.1 | $10M | +30% | 335k | 29.84 |
|
| Bioage Labs Call Option (BIOA) | 3.1 | $9.9M | NEW | 405k | 24.51 |
|
| Inventiva Sa Ads (IVA) | 2.9 | $9.2M | +355% | 2.4M | 3.78 |
|
| Adlai Nortye Sponsored Ads (ANL) | 2.7 | $8.8M | -39% | 765k | 11.50 |
|
| Compass Pathways Sponsored Ads (CMPS) | 2.7 | $8.6M | NEW | 605k | 14.15 |
|
| Enliven Therapeutics (ELVN) | 2.5 | $8.1M | NEW | 160k | 50.75 |
|
| Rezolute Com New (RZLT) | 2.1 | $6.8M | NEW | 1.3M | 5.20 |
|
| Arrivent Biopharma Call Option (AVBP) | 2.0 | $6.4M | +66% | 183k | 34.74 |
|
| Palisade Bio (PALI) | 1.9 | $6.3M | 3.0M | 2.09 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 1.9 | $6.1M | -14% | 3.0M | 2.03 |
|
| Adagene Ads (ADAG) | 1.6 | $5.3M | NEW | 1.3M | 4.20 |
|
| Forte Biosciences Com New (FBRX) | 1.5 | $4.8M | NEW | 225k | 21.25 |
|
| Inflarx Nv (IFRX) | 1.4 | $4.5M | NEW | 2.0M | 2.24 |
|
| Assembly Biosciences Com New (ASMB) | 1.4 | $4.4M | NEW | 160k | 27.48 |
|
| Promis Neurosciences Com Shs (PMN) | 1.3 | $4.3M | 325k | 13.16 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 1.3 | $4.3M | NEW | 260k | 16.39 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.2 | $4.0M | NEW | 85k | 47.04 |
|
| Sol-gel Technologies Shs New (SLGL) | 1.2 | $3.9M | +67% | 52k | 74.14 |
|
| Scynexis | 1.0 | $3.1M | NEW | 757k | 4.07 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.9 | $2.8M | NEW | 1.5M | 1.86 |
|
| Disc Medicine Call Option (IRON) | 0.7 | $2.2M | NEW | 30k | 73.14 |
|
| Lipocine Com New (LPCN) | 0.6 | $2.1M | +80% | 810k | 2.56 |
|
| Ultragenyx Pharmaceutical Call Option (RARE) | 0.6 | $1.8M | NEW | 55k | 33.39 |
|
| Cue Biopharma (CUE) | 0.5 | $1.6M | NEW | 50k | 31.56 |
|
| Calcimedica Com New (CALC) | 0.4 | $1.3M | NEW | 1.2M | 1.03 |
|
| Quince Therapeutics | 0.2 | $734k | NEW | 40k | 18.19 |
|
| Nuvectis Pharma Call Option (NVCT) | 0.2 | $712k | NEW | 39k | 18.39 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.2 | $515k | -52% | 1.0M | 0.52 |
|
| Inmed Pharmaceuticals Com New (INM) | 0.2 | $504k | NEW | 325k | 1.55 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $170k | NEW | 100k | 1.70 |
|
| Nextcure Com New (NXTC) | 0.0 | $103k | -75% | 65k | 1.60 |
|
Past Filings by Squadron Capital Management
SEC 13F filings are viewable for Squadron Capital Management going back to 2026
- Squadron Capital Management 2026 Q2 filed Aug. 14, 2026
- Squadron Capital Management 2026 Q1 filed May 15, 2026